Neovii Pharmaceuticals AG announced a significant change to its executive leadership team. Dr. Christian Loss will retire from his role as Chief Executive Officer (CEO). Frédéric Prince, PhD, will succeed him effective January 1, 2026. Dr. Prince recently served as Head of Strategy at Roche. He brings a wealth of experience in oncology and drug development. This transition marks a new chapter for the Swiss-based company. The board expects Dr. Prince to drive future growth and development.
The new leader has a strong background in biotechnology and genetics. At Roche, he managed early development programs in immuno-oncology. He also held senior roles at Bluebird Bio and Novartis Oncology. His career spans over a decade across several major global markets. This diverse experience includes both research and commercial functions. He holds a PhD in Molecular Genetics from the University of Basel. Neovii Pharmaceuticals AG will benefit from his deep scientific and business expertise.
Strategic Leadership at Neovii Pharmaceuticals AG
The company remains dedicated to improving patient outcomes through science. The outgoing CEO, Dr. Christian Loss, will join the Board of Directors. This ensures his deep knowledge stays within the organization. The board expressed great confidence in the new leadership direction. They thanked Dr. Loss for his years of successful service. The firm continues to focus on life-changing therapies for patients worldwide.
The Board of Directors shared these thoughts on the new appointment.
“The Board of Directors extends a warm welcome to Dr. Prince and is confident that he will drive Neovii’s continued growth and development. At the same time, the Board would like to express its heartfelt thanks to Dr. Christian Loss for his decades of dedicated service, his successful leadership, and invaluable contributions to the development of Neovii Pharmaceuticals.”
The official statement highlighted the legacy left by the retiring executive.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
